Independent Nurse: Clinical - Focus - Schizophrenia

Walters, Paul
March 2006
GP: General Practitioner;3/3/2006, p103
The article presents information related to schizophrenia. Schizophrenia is a severe mental illness that commonly starts in early adulthood and runs a relapsing and remitting course. Diagnosis is based on clusters of symptoms being present for a defined period of time, often one month or longer. Atypical antipsychotics are recommended as first-line treatment for patients with a first-onset psychotic episode and those who, despite having adequate symptom control on conventional antipsychotics, suffer side-effects.


Related Articles

  • The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs. Four rare cases in Ireland. Waddington, John L.; Youssef, Hanafy A.; Waddington, J L; Youssef, H A // British Journal of Psychiatry;Jan90, Vol. 156, p106 

    Four elderly schizophrenic patients who had never been treated with neuroleptics, and a fifth patient who had received only the briefest exposure to such drugs, had retained their distinct clinical characteristics. Involuntary orofacial movements and cognitive dysfunction were found more...

  • Quantitative EEG in Schizophrenic Patients before and during Pharmacotherapy. Begić, Dražen; Hotujac, Ljubomir; Jokić-Begić, Nataša // Neuropsychobiology;2000, Vol. 41 Issue 3, p166 

    The aim of the study was to determine the possible differences in quantitative EEG parameters of schizophrenic patients before and during therapy with neuroleptics. First EEG recordings were obtained from schizophrenic patients (n = 50) who had not been taking any medicaments during the...

  • The promise of new drugs for schizophrenia treatment. Tamminga, C. A.; Tamminga, Ca // Canadian Journal of Psychiatry;Apr1997, Vol. 42 Issue 3, p265 

    Objective: To present aspects of preclinical and clinical pharmacology of new antipsychotic drugs and to emphasize those preclinical drug characteristics which might predict desirable clinical actions.Method: Review of the relevant literature and publicly presented...

  • Plasma Omentin Levels in Drug-Free Patients with Schizophrenia. Yildirim, Osman; Canan, Fatih; Tosun, Mehmet; Kayka, Nefise; Tuman, Taha Can; alhan, Cafer; alcelik, aytekin // Neuropsychobiology;Jun2014, Vol. 69 Issue 3, p159 

    Aims: We aimed to investigate plasma omentin concentrations in non-obese, drug-free patients with schizophrenia in comparison with healthy volunteers. Method: Thirty-two patients with schizophrenia and 33 control subjects were recruited. Plasma omentin levels were determined by enzyme-linked...

  • Duration of untreated psychotic illness. Peralta, Victor; Cuesta, Manuel; Martinez-Larrea, Alfredo; Serrano, Jose; Langarica, Myriam // Social Psychiatry & Psychiatric Epidemiology;May2005, Vol. 40 Issue 5, p345 

    Abstract Background A lengthy delay often exists be- tween the onset of psychotic symptoms and the start of appropriate treatment. However, the causes of this long delay remain poorly understood, and there is a need to search for the factors involved in such a delay in order to reduce the time...

  • Paliperidone: the evidence of its therapeutic value in schizophrenia. Kantrowitz, Joshua; Citrome, Leslie // Core Evidence;2008, Vol. 2 Issue 4, p261 

    Introduction: Paliperidone, the 9-hydroxy metabolite of risperidone, is a second-generation antipsychotic that was recently approved for the treatment of schizophrenia. It is marketed as an improvement over risperidone, but is likely to be considerably more costly when risperidone is no longer...

  • Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues. Brabbins, Clare; Butler, Jonathan; Bentall, Richard; Brabbins, C; Butler, J; Bentall, R // British Journal of Psychiatry;May96, Vol. 168, p540 

    Background: The effects of neuroleptic medication on schizophrenic patients are both positive (reduction in symptoms) and negative (adverse side-effects). Given that altered cognitive functioning may be a feature of schizophrenia, the use of neuroleptics raises important ethical and...

  • The Therapeutic Relationship and Adherence to Antipsychotic Medication in Schizophrenia. McCabe, Rosemarie; Bullenkamp, Jens; Hansson, Lars; Lauber, Christoph; Martinez-Leal, Rafael; Rössler, Wulf; Salize, Hans Joachim; Svensson, Bengt; Torres-Gonzalez, Francisco; van den Brink, Rob; Wiersma, Durk; Priebe, Stefan // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Objective: Previous research has shown that a better therapeutic relationship (TR) predicts more positive attitudes towards antipsychotic medication, but did not address whether it is also linked with actual adherence. This study investigated whether the TR is associated with adherence to...

  • Why we should use long-acting injectable antipsychotics more frequently. Maia-de-Oliveira, João Paulo; Bressan, Rodrigo A.; Elkis, Hello; Machado-de-Sousa, João Paulo; Hallak, Jaime E. C. // Revista Brasileira de Psiquiatria;Jul-Sep2013, Vol. 35 Issue 3, p217 

    The author discusses the reason for the need to use long-acting injectable antipsychotics more often. Depot antipsychotic drugs, or long-acting injectable antispsychotics (LAI), have been in the market since the 1960s and were regarded primarily to enhance compliance to treatment in patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics